Immune-Related Cystitis Following Immune Checkpoint Inhibitor Therapy: A Report of Two Cases
Abstract
In recent years, immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for a variety of cancers, yet they are associated with immune-related adverse events (irAEs). Although irAEs commonly affect the skin, gastrointestinal tract, lungs, and endocrine glands, immune-related cystitis and ureteritis are extremely rare and often overlooked. We report on two patients who developed immune-mediated ureteritis and cystitis following treatment with PD-1 inhibitors (tislelizumab and toripalimab). Both patients exhibited urinary frequency, urgency, dysuria, and hematuria without evidence of infection and were unresponsive to empirical antibiotics. Imaging results, combined with clinical symptoms, confirmed the diagnosis of urinary tract irAEs. Symptoms improved markedly following systemic glucocorticoid therapy. Through case analysis and a targeted literature review, we have summarized diagnostic indicators, therapeutic principles, and steroid tapering strategies for managing ICI-associated urinary irAEs. We emphasize the importance of early recognition and standardized management to prevent permanent damage and offer practical guidance for clinicians dealing with these uncommon but clinically significant toxicities.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.